Bicyclic Anilide Heterocyclic CGRP Antagonists for Migraine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders involving CGRP, such as migraine and cluster headache, are limited in efficacy and specificity, as existing antagonists may have side effects and are not effective for all patients.
Innovation Solution
Development of novel compounds that act as selective antagonists of CGRP receptors, specifically designed to target and inhibit CGRP receptor activity, thereby reducing the symptoms associated with these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CGRP antagonists are used for treatment, then some therapeutic effect is achieved, but side effects occur and efficacy is limited
Solution Approach 1:
The patent applies local quality by designing a bicyclic anilide heterocyclic structure with specific functional groups positioned at defined locations (R1-R6 substituents) to achieve selective binding to CGRP receptors. The localized structural features enable specific interaction with the receptor site while avoiding non-specific interactions that cause side effects, thus improving therapeutic efficacy and reducing adverse reactions.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters including the bicyclic heterocycle core structure, anilide linkage configuration, and multiple substituent positions (R1-R6) to optimize receptor affinity and selectivity. These structural parameter modifications enhance binding specificity to CGRP receptors, improving therapeutic effectiveness while minimizing off-target effects.
2Reliability
If existing CGRP antagonists are used, then treatment is provided, but specificity and effectiveness are insufficient
Solution Approach 1:
The patent achieves enhanced receptor specificity through local quality by incorporating a bicyclic anilide heterocyclic core with specifically positioned functional groups. The defined substituent positions (R1-R6) create a unique molecular recognition pattern that selectively binds to CGRP receptors, improving both specificity and treatment effectiveness for migraine and cluster headache conditions.
Solution Approach 2:
The patent applies asymmetry by utilizing the inherent chirality and asymmetric substitution patterns of the bicyclic anilide heterocyclic structure. The non-symmetric arrangement of functional groups and substituents at specific positions creates a three-dimensional binding interface that selectively interacts with the chiral binding site of CGRP receptors, enhancing both specificity and therapeutic effectiveness.
Data Source
AI summary
Compounds of formula I:(wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.